Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.
|Original language||English (US)|
|Journal||Chinese Pharmacological Bulletin|
|State||Published - Jan 1 2009|
- Adverse effect
- Rational administration
- Tumor necrosis factor blocker
ASJC Scopus subject areas